Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Sientra (NASDAQ: SIEN) today and set a price target of $25. The company’s shares closed yesterday at $21.38, close to its 52-week high of $21.91.
According to TipRanks.com, Block is a 5-star analyst with an average return of 23.1% and a 75.9% success rate. Block covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Idexx Laboratories, and Align Tech.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sientra with a $22.25 average price target.
See today’s analyst top recommended stocks >>
Based on Sientra’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $18.03 million. In comparison, last year the company had a GAAP net loss of $20.39 million.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SIEN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. Its products include breast implants, breast tissue expanders, silicone scar treatment, and additional tissue expanders. The company was founded by Hani M. Zeini in 2006 and is headquartered in Santa Barbara, CA.
